Bryce Point Capital LLC Makes New $607,000 Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Bryce Point Capital LLC purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,703 shares of the biopharmaceutical company’s stock, valued at approximately $607,000.

Other large investors have also made changes to their positions in the company. Norges Bank bought a new position in Halozyme Therapeutics during the fourth quarter worth about $60,054,000. Arrowstreet Capital Limited Partnership raised its position in shares of Halozyme Therapeutics by 141.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company’s stock worth $47,470,000 after purchasing an additional 581,475 shares during the period. Raymond James Financial Inc. bought a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $21,838,000. Vanguard Group Inc. grew its position in shares of Halozyme Therapeutics by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company’s stock valued at $634,999,000 after purchasing an additional 386,618 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in Halozyme Therapeutics by 698.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock worth $13,756,000 after purchasing an additional 251,711 shares in the last quarter. Institutional investors own 97.79% of the company’s stock.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,200 shares of company stock valued at $1,786,668. 2.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HALO shares. Piper Sandler lifted their price target on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Wells Fargo & Company dropped their price objective on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Benchmark reiterated a “buy” rating and set a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $62.78.

Halozyme Therapeutics Trading Up 1.9 %

Shares of NASDAQ:HALO opened at $63.02 on Thursday. The company’s 50-day moving average price is $59.62 and its two-hundred day moving average price is $54.90. Halozyme Therapeutics, Inc. has a one year low of $37.73 and a one year high of $66.00. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15. The stock has a market capitalization of $7.79 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32.

Halozyme Therapeutics (NASDAQ:HALO) last released its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million for the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.